This federal Project Grant award of $1,638,033, provided by the National Institutes of Health (NIH) under the Biomedical Research and Research Training Program (CFDA 93.859), supports the development of a CRISPR-free mammalian recombineering system at the Scripps Research Institute. The project aims to characterize and optimize a bacterial recombinase system for efficiently conducting large-scale DNA insertions, deletions, and substitutions in mammalian cells without inducing cytotoxic double-strand breaks. The research team plans to further engineer the recombineering system, including through directed evolution, and demonstrate its utility by applying it to cell models of Gaucher disease. The award has a project period from September 1, 2024 to August 31, 2027.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $1.6m | 8/29/24 |